您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > Nitazoxanide D4
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Nitazoxanide D4
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Nitazoxanide D4图片
CAS NO:1246819-17-9
规格:≥98%
包装与价格:
包装价格(元)
2mg电议
5mg电议
10mg电议
25mg电议
50mg电议

产品介绍
理化性质和储存条件
Molecular Weight (MW)311.31
FormulaC12H5D4N3O5S
CAS No.1246819-17-9 (Nitazoxanide D4);
Storage-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)DMSO:10 mM
Water: <1 mg/mL
Ethanol: <1 mg/mL
SMILES CodeO=C(NC1=NC=C([N+]([O-])=O)S1)C2=C(OC(C)=O)C([2H])=C([2H])C([2H])=C2[2H]
SynonymsNTZ D4; NSC 697855 D4; NSC-697855; NSC697855 D4; Nitazoxanide D4, Alinia, Colufase, Daxon, Nitazoxamide D4
实验参考方法
In Vitro

In vitro activity: Nitazoxanide reduces parasite growth in cell culture by more than 90% with little evidence of drug-associated cytotoxicity. Nitazoxanide is a new thiazolide antiparasitic agent that shows excellent in vitro activity against a wide variety of protozoa and helminths. Nitazoxanide and its metabolite tizoxanide are more active in vitro than metronidazole against G. intestinalis, E. histolytica and T. vaginalis. Nitazoxanide exhibits potent inhibition of both HBV and HCV replication. Nitazoxanide potentiates the effect of subsequent treatment with Nitazoxanide plus IFN, but not Nitazoxanide plus 2'CmeC, in HCV replicon-containing cells. Nitazoxanide induces reductions in several HBV proteins (HBsAg, HBeAg, HBcAg) produced by 2.2.15 cells, but does not affect HBV RNA transcription. Nitazoxanide exhibits IC50, and IC90 values of 0.017 and 0.776 mg/mL respectively, against E. histolytica, 0.004 and 0.067 mg/mL against G. intestinalis, and 0.034 and 2.046 mg/mL against T. vaginalis. Nitazoxanide is more toxic than metronidazole and albendazole against E. histolytica.

In VivoNitazoxanide is partially effective at reducing the parasite burden in a gnotobiotic piglet diarrhea model when given orally for 11 days at 250 mg/kg/day but not at 125 mg/kg/day. Nitazoxanide induces a drug-related diarrhea in piglets that might have influenced its therapeutic efficacy.
Animal modelGnotobiotic piglet diarrhea model
Formulation & Dosage125, 250 mg/kg; oral
References

Antimicrob Agents Chemother. 1998 Aug;42(8):1959-65; Clin Infect Dis. 2005 Apr 15;40(8):1173-80; J Antimicrob Chemother. 2002 Jan;49(1):103-11.